This study aimed to analyze the tumor microenvironment based on tumor PD-L1 expression, serum exosomal PD-L1, and CD8+ TILs to investigate the anti-PD-1 response and clinicopathological outcomes in NSCLC. This evidence concerns the gene CD8A and non-small cell lung carcinoma.